---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-026931"
form_type: "8-K"
ticker: "OMER"
cik: "0001285819"
company_name: "OMEROS CORP"
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T12:52:10.497041+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Omeros Q2 net loss narrows to $25.4M; narsoplimab PDUFA extended to Dec 2025; debt reduced by $80M

## Summary
- Net loss of $25.4M ($0.43/sh) vs $56.0M ($0.97/sh) a year ago; cash, short-term investments $28.7M at June 30.
- Post-quarter: raised $20.6M net from Polar Asset Management (5.37M shares at $4.10, 14% premium) plus $2.1M from ATM.
- Narsoplimab BLA PDUFA date extended to Dec 26, 2025; FDA expects labeling talks by Oct. EMA MAA validated, opinion mid-2026.
- Exchanged $70.8M of 2026 Notes for 2029 Notes; remaining 2026 Notes reduced to $17.1M; avoided $20M prepayment on term debt.
- In talks for potential asset deal with multi-billion total value; upfront cash would repay $67.1M term loan and $17.1M notes.

## SEC filing metadata
- accession: 0001437749-25-026931
- form_type: 8-K
- ticker: OMER
- cik: 0001285819
- company_name: OMEROS CORP
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285819/000143774925026931/0001437749-25-026931-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285819/000143774925026931/omer20250521_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-026931
- JSON: https://secwatch.observer/filing/0001437749-25-026931.json
- Plain text: https://secwatch.observer/filing/0001437749-25-026931.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.